Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian Multicenter Study.

Liccardi G, Calzetta L, Bilò MB, Brusca I, Cecchi L, Costantino MT, Da Re M, Buzzulini F, Giani M, Lombardi C, Meneguzzi G, Meriggi A, Milanese M, Onida R, Patella V, Pignatti P, Quercia O, Ridolo E, Sabatino G, Sacerdoti C, Savi E, Scala E, Steinhilber G, Villalta D, Passalacqua G, Rogliani P; Italian Allergic Respiratory Diseases Task Force.

J Allergy Clin Immunol Pract. 2020 Mar 12. pii: S2213-2198(20)30242-7. doi: 10.1016/j.jaip.2020.02.041. [Epub ahead of print] No abstract available.

PMID:
32173510
2.

Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review.

Calzetta L, Ritondo BL, Matera MG, Cazzola M, Rogliani P.

Expert Rev Respir Med. 2020 Mar 13. doi: 10.1080/17476348.2020.1743180. [Epub ahead of print]

PMID:
32168461
3.

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.

Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM.

Risk Manag Healthc Policy. 2020 Jan 22;13:43-53. doi: 10.2147/RMHP.S211321. eCollection 2020.

4.

Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease.

Cazzola M, Cavalli F, Usmani OS, Rogliani P.

Expert Opin Drug Deliv. 2020 Mar 16:1-12. doi: 10.1080/17425247.2020.1739021. [Epub ahead of print]

PMID:
32130023
5.

The possible concomitant use of aeroallergen and food panels for skin prick testing might enhance the risk of generalized allergic reactions in children.

Liccardi G, Calzetta L, Milanese M, Apicella G, Rogliani P.

Turk J Pediatr. 2019;61(5):815-816. doi: 10.24953/turkjped.2019.05.027. No abstract available.

6.

TSLP Inhibitors for Asthma: Current Status and Future Prospects.

Matera MG, Rogliani P, Calzetta L, Cazzola M.

Drugs. 2020 Apr;80(5):449-458. doi: 10.1007/s40265-020-01273-4.

PMID:
32078149
7.

α1-Antitrypsin deficiency and chronic respiratory disorders.

Cazzola M, Stolz D, Rogliani P, Matera MG.

Eur Respir Rev. 2020 Feb 12;29(155). pii: 190073. doi: 10.1183/16000617.0073-2019. Print 2020 Mar 31. Review.

8.

Severe Asthma and Biological Therapy: When, Which, and for Whom.

Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M.

Pulm Ther. 2019 Dec 26. doi: 10.1007/s41030-019-00109-1. [Epub ahead of print] Review.

PMID:
32048241
9.

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Pulm Ther. 2019 Dec;5(2):117-126. doi: 10.1007/s41030-019-00102-8. Epub 2019 Nov 2. Review.

10.

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life.

Sposato B, Camiciottoli G, Bacci E, Scalese M, Carpagnano GE, Pelaia C, Santus P, Maniscalco M, Masieri S, Corsico A, Scichilone N, Baglioni S, Murgia N, Folletti I, Bardi G, Grosso A, Cameli P, Latorre M, Musarra A, Bargagli E, Ricci A, Pelaia G, Paggiaro P, Rogliani P.

Pulm Pharmacol Ther. 2020 Apr;61:101899. doi: 10.1016/j.pupt.2020.101899. Epub 2020 Jan 21.

PMID:
31972327
11.

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics.

Principe S, Benfante A, Calzetta L, Rogliani P, Scichilone N.

World Allergy Organ J. 2019 Nov 6;12(11):100081. doi: 10.1016/j.waojou.2019.100081. eCollection 2019 Nov.

12.

A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study.

Calzetta L, Matera MG, Goldstein MF, Fairweather WR, Howard WW, Cazzola M, Rogliani P.

Pulm Pharmacol Ther. 2020 Feb;60:101883. doi: 10.1016/j.pupt.2019.101883. Epub 2019 Dec 26.

13.

The future of bronchodilation: looking for new classes of bronchodilators.

Cazzola M, Rogliani P, Matera MG.

Eur Respir Rev. 2019 Dec 23;28(154). pii: 190095. doi: 10.1183/16000617.0095-2019. Print 2019 Dec 31. Review.

14.

Pharmacology and Therapeutics of Bronchodilators Revisited.

Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M.

Pharmacol Rev. 2020 Jan;72(1):218-252. doi: 10.1124/pr.119.018150. Review.

PMID:
31848208
15.

Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy? Possible Explanations.

Liccardi G, Calzetta L, Milanese M, Bilò MB, Rogliani P.

J Investig Allergol Clin Immunol. 2019 Dec;29(6):472-473. doi: 10.18176/jiaci.0429. No abstract available.

16.

Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study.

Contoli M, Rogliani P, Di Marco F, Braido F, Corsico AG, Amici CA, Piro R, Sarzani R, Lessi P, Scognamillo C, Scichilone N, Santus P; SAT Study Group.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619888128. doi: 10.1177/1753466619888128.

17.

Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience.

Cefalo M, Puxeddu E, Sarmati L, Paterno G, Fontana C, Nasso D, Pane G, De Bellis E, Palmieri R, Buzzati E, Meconi F, Laureana R, Casciani P, Zizzari AG, Rogliani P, de Fabritiis P, Maurillo L, Buccisano F, Cantonetti M, Arcese W, Venditti A, Del Principe MI.

Mediterr J Hematol Infect Dis. 2019 Nov 1;11(1):e2019065. doi: 10.4084/MJHID.2019.065. eCollection 2019.

18.

Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.

Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L.

Br J Pharmacol. 2020 Mar;177(5):1150-1163. doi: 10.1111/bph.14909. Epub 2020 Jan 29.

PMID:
31660611
19.

Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.

Calzetta L, Matera MG, Cazzola M, Rogliani P.

Adv Ther. 2019 Dec;36(12):3291-3298. doi: 10.1007/s12325-019-01119-w. Epub 2019 Oct 25.

20.

The impact of comorbidities on severe asthma.

Rogliani P, Sforza M, Calzetta L.

Curr Opin Pulm Med. 2020 Jan;26(1):47-55. doi: 10.1097/MCP.0000000000000640.

PMID:
31644439
21.

Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.

Calzetta L, Di Marco F, Blasi F, Cazzola M, Centanni S, Micheletto C, Rossi A, Rogliani P.

Pulm Pharmacol Ther. 2019 Dec;59:101855. doi: 10.1016/j.pupt.2019.101855. Epub 2019 Oct 19.

PMID:
31639476
22.

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2019 Dec;59:101841. doi: 10.1016/j.pupt.2019.101841. Epub 2019 Sep 11.

PMID:
31520718
23.

Pharmacological treatment and current controversies in COPD.

Cazzola M, Rogliani P, Stolz D, Matera MG.

F1000Res. 2019 Aug 29;8. pii: F1000 Faculty Rev-1533. doi: 10.12688/f1000research.19811.1. eCollection 2019. Review.

24.

Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study.

Radovanovic D, Contoli M, Marco FD, Sotgiu G, Pelaia G, Braido F, Corsico AG, Micheletto C, Rogliani P, Scichilone N, Saderi L, Santus P, Solidoro P.

COPD. 2019 Aug;16(3-4):215-226. doi: 10.1080/15412555.2019.1659760. Epub 2019 Sep 9.

PMID:
31500459
25.

Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Expert Opin Investig Drugs. 2019 Oct;28(10):827-833. doi: 10.1080/13543784.2019.1661990. Epub 2019 Sep 1. Review.

PMID:
31474120
26.

Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.

Vancheri C, Sebastiani A, Tomassetti S, Pesci A, Rogliani P, Tavanti L, Luppi F, Harari S, Rottoli P, Ghirardini A, Kirchgaessler KU, Albera C.

Respir Med. 2019 Sep;156:78-84. doi: 10.1016/j.rmed.2019.08.006. Epub 2019 Aug 13.

PMID:
31445389
27.

Ultra-LABAs for the treatment of asthma.

Cazzola M, Rogliani P, Matera MG.

Respir Med. 2019 Sep;156:47-52. doi: 10.1016/j.rmed.2019.08.005. Epub 2019 Aug 12. Review.

PMID:
31425937
28.

A potential role of triple therapy for asthma patients.

Cazzola M, Puxeddu E, Matera MG, Rogliani P.

Expert Rev Respir Med. 2019 Nov;13(11):1079-1085. doi: 10.1080/17476348.2019.1657408. Epub 2019 Sep 1.

PMID:
31422716
29.

Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?

Liccardi G, Calzetta L, Milanese M, Bilò MB, Rogliani P.

Int Arch Allergy Immunol. 2019;180(2):142-143. doi: 10.1159/000501796. Epub 2019 Aug 14. No abstract available.

PMID:
31412331
30.

Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis.

Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG.

Multidiscip Respir Med. 2019 Aug 3;14:25. doi: 10.1186/s40248-019-0189-0. eCollection 2019.

31.

Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.

Cazzola M, Puxeddu E, Ora J, Rogliani P.

Mol Diagn Ther. 2019 Oct;23(5):603-614. doi: 10.1007/s40291-019-00413-1. Review.

PMID:
31363933
32.

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment.

Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M.

Pulm Pharmacol Ther. 2019 Oct;58:101828. doi: 10.1016/j.pupt.2019.101828. Epub 2019 Jul 23. Review.

PMID:
31349002
33.

CD71- Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease.

Puxeddu E, Fraboni D, Cillis G, Cavalli F, Buccisano F, Rogliani P.

Am J Respir Crit Care Med. 2019 Dec 1;200(11):1444-1446. doi: 10.1164/rccm.201906-1159LE. No abstract available.

34.

Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis.

Ricci F, Pugliese L, Cavallo AU, Forcina M, De Stasio V, Presicce M, Di Tosto F, Di Donna C, Spiritigliozzi L, Rogliani P, Floris R, Chiocchi M.

Acta Radiol. 2020 Feb;61(2):204-218. doi: 10.1177/0284185119857435. Epub 2019 Jun 25. Review. No abstract available.

PMID:
31237771
35.

Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.

Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, Lauro D.

Respir Med. 2019 Jul - Aug;154:86-92. doi: 10.1016/j.rmed.2019.06.015. Epub 2019 Jun 18.

PMID:
31228775
36.

Corrigendum to "Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up" [Respir. Med. 153 (2019) 68-75].

Corsico AG, Braido F, Contoli M, Di Marco F, Rogliani P, Scognamillo C, Olivi I, Santus P, Scichilone N, Lazzaro C.

Respir Med. 2019 Nov - Dec;160:105724. doi: 10.1016/j.rmed.2019.06.009. Epub 2019 Jun 13. No abstract available.

PMID:
31202574
37.

Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up.

Corsico AG, Braido F, Contoli M, Di Marco F, Rogliani P, Scognamillo C, Olivi I, Santus P, Scichilone N, Lazzaro C.

Respir Med. 2019 Jul;153:68-75. doi: 10.1016/j.rmed.2019.05.017. Epub 2019 May 29. Erratum in: Respir Med. 2019 Jun 12;:.

PMID:
31174106
38.

Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.

Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG.

Trends Pharmacol Sci. 2019 Jul;40(7):452-463. doi: 10.1016/j.tips.2019.04.015. Epub 2019 May 27. Review.

PMID:
31147200
39.

Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.

Matera MG, Calzetta L, Rogliani P, Cazzola M.

Respir Med. 2019 Jul;153:3-13. doi: 10.1016/j.rmed.2019.05.005. Epub 2019 May 13. Review.

PMID:
31136930
40.

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.

Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L.

Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.

41.

Monoclonal antibodies in severe asthma: is it worth it?

Calzetta L, Matera MG, Rogliani P.

Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):517-520. doi: 10.1080/17425255.2019.1621837. Epub 2019 May 23.

PMID:
31104515
42.

Response.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 May;155(5):1079-1080. doi: 10.1016/j.chest.2019.01.028. No abstract available.

PMID:
31060694
43.

Bronchodilators in subjects with asthma-related comorbidities.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Respir Med. 2019 May;151:43-48. doi: 10.1016/j.rmed.2019.04.001. Epub 2019 Apr 3. Review.

PMID:
31047116
44.

Cardiovascular Disease in Chronic Respiratory Disorders and Beyond.

Rogliani P, Cazzola M, Calzetta L.

J Am Coll Cardiol. 2019 May 7;73(17):2178-2180. doi: 10.1016/j.jacc.2018.11.068. No abstract available.

PMID:
31047005
45.

Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes.

Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Ricci A, Cresti A, Santus P, Olivieri C, Perrella A, Rogliani P, Paggiaro P; Omalizumab Italian Study Group.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1643-1646. doi: 10.1016/j.jaip.2019.03.006. Epub 2019 Mar 19. No abstract available.

PMID:
30898690
46.

Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.

Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG.

Pulm Pharmacol Ther. 2019 Jun;56:39-50. doi: 10.1016/j.pupt.2019.03.004. Epub 2019 Mar 12.

PMID:
30876907
47.

Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it.

Liccardi G, Calzetta L, Milanese M, Passalacqua G, Rogliani P.

J Allergy Clin Immunol. 2019 Apr;143(4):1657-1658. doi: 10.1016/j.jaci.2018.12.1007. Epub 2019 Feb 10. No abstract available.

PMID:
30745148
48.

Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease.

Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J.

Expert Opin Pharmacother. 2019 Apr;20(6):737-750. doi: 10.1080/14656566.2019.1570133. Epub 2019 Feb 1. Review.

PMID:
30707637
49.

The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.

Harari S, Caminati A, Confalonieri M, Poletti V, Vancheri C, Pesci A, Rogliani P, Luppi F, Agostini C, Rottoli P, Sanduzzi Zamparelli A, Sebastiani A, Della Porta R, Salton F, Messore B, Tomassetti S, Rosso R, Biffi A, Puxeddu E, Cerri S, Cinetto F, Refini RM, Bocchino M, Di Michele L, Specchia C, Albera C; ILDINET (Interstitial Lung Diseases Italian Network).

Clin Respir J. 2019 Mar;13(3):166-173. doi: 10.1111/crj.12999.

PMID:
30675755
50.

Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17. Review.

PMID:
30660781

Supplemental Content

Loading ...
Support Center